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Abstract
Background: Hypoxia-inducible factor 1 alpha (HIF-1α) and vascular endothelial growth factor
(VEGF) are frequently overexpressed in numerous types of cancers and are known to be important
regulators of angiogenesis. Until now, few studies have been carried out to investigate the
prognostic role of these factors in solid tumors, especially in colorectal cancer (CRC). The purpose
of this study was to evaluate the expression of HIF-1α and VEGF in CRC tissues, and to analyze
the association of these two factors with several clinical and pathological characteristics, and
patients' survival.
Methods:  Paraffin-embedded tissue samples were retrospectively collected from 71 CRC
patients, who received surgical resection between 2001 and 2002, with a median follow-up of 5
years. We examined the patterns of expression of HIF-1α and VEGF by immunohistochemistry
method. Statistical analysis was performed with univariate tests and multivariate Cox proportional
hazards model to evaluate the differences.
Results: Expression of HIF-1α and VEGF was positively observed in 54.93% and 56.34% among the
patients, respectively. HIF-1α and VEGF status were significantly associated with tumor stage,
lymph nodes and liver metastases (P < 0.05). Expression of both HIF-1α and VEGF remained
significantly associated with overall survival (OS) (P < 0.01), and HIF-1α was positively correlative
to VEGF in CRC (r = 0.72, P < 0.001).
Conclusions: HIF-1α and VEGF could be used as biomarkers indicating tumors in advanced stage
and independently implied poor prognosis in patients with CRC. Treatment that inhibits HIF-1α
might be a promising targeted approach in CRC to exhibit its potential to improve outcomes in
future perspective, just as VEGF targeting has proved to be.
Background
Colorectal cancer (CRC) still accounts for a high morbid-
ity and mortality, worldwide, in men and women [1]. Ear-
lier diagnosis, better acknowledge of its clinical
prognostic factors and surgical treatment combined with
chemotherapy or radiotherapy had contributed to the
improved efficacy and clinical outcomes of the affected
patients. Significant improvements have been made in the
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management of this disease mainly through the adminis-
tration of active chemotherapeutic agents, involving oxali-
platin and irinotecan, combined with fluorouracil [2,3].
In recent years, advances in understanding tumor biology
have led to the development of targeted therapies making
progress in the treatment of CRC [4-6]. The most signifi-
cant and independent prognostic factors accepted to date
in CRC remain the TNM (tumor-node-metastasis) stage
according to the initial surgery [7]. Moreover several other
factors providing predictive value for survival have been
identified, but only a few of them have shown to have an
impact on CRC patients' prognosis and survival including
'potential' residual disease, obstruction, histology perfora-
tion, venous invasion and inadequate number of lymph
nodes evaluated [8]. In fact, some prognostic factors are
still unknown. Although TNM classification is useful for
staging and selecting patients for specific treatment, this
classification is insufficient as many patients at the same
stage may have various outcomes. Hence, additional prog-
nostic biomarkers are really needed for the management
of CRC patients nowadays.
Insufficient levels of cellular O2, a condition known as
hypoxia, were demonstrated in pathological states due to
rapid proliferation of tumor cells. Hypoxia exists in
microenvironment in many tumor entities due to struc-
tural and functional abnormality of vessels and increasing
oxygen consumption caused by rapid proliferation of
tumor cells. Hypoxia inducible factor-1 (HIF-1), a tran-
scriptional complex, which generally resides in anoxic
mammal and human cells, has already been identified as
one critical protein directly reacting to hypoxia [9]. No
tumors grow larger than 2 mm3 in the absence of angio-
genesis because lack of oxygen in the center of the tumor
results in cell apoptosis and necrosis. Reduced oxygen ten-
sion (hypoxia) is a key signal for the induction of angio-
genesis, and one of the key angiogenic factors regulated by
hypoxia is VEGF [10]. All these factors are under the con-
trol of HIF-1 which specially binds to the hypoxia
response element (HRE) that includes cis-acting DNA ele-
ments recognized by multiple transactivators [11]. HIF-1
is a heterodimer composed of HIF-1alpha (HIF-1α) and
HIF-1beta (HIF-1β) subunits. HIF-1β, also known as aryl
hydrocarbon receptor nuclear translocator, is constitu-
tively expressed, whereas HIF-1α activates the expression
of VEGF gene by binding to the HRE in the VEGF pro-
moter region [12,13].
Above all, HIF-1α and VEGF are both important regula-
tors of angiogenesis. Understanding association of
tumour biology with clinical features is crucial for the
development of antiangiogenic therapy. Although HIF-1α
and VEGF were reported to be expressed in many types of
cancers, few studies which investigate the clinical value of
these factors in solid tumors, in particular, in human CRC,
have yet been reported. The purpose of our study was to
investigate the impact of HIF-1α and VEGF expression on
clinical outcomes and prognosis in human CRC. Moreo-




Eighty paraffin-embedded tumor samples were available
from 80 consecutive patients diagnosed in our hospital
with CRC between January 2001 and March 2002. Two
patients were excluded who had only simple biopsies due
to loco-regional extension and seven patients were lost to
follow up. Finally, 71 patients were evaluated in the clin-
ical and histological study and for the survival analysis.
Samples of normal tissue retrieved up to 5 centimeters
away from the tumor's edge were taken as negative con-
trols. Forty-three out of 71 patients were male. The
median age was 56.2 ± 10.5 (29-75). No patients had his-
tory of chemotherapy or radiotherapy before surgery. The
present study involving the human tissue samples was
approved by the medical ethics committee of West China
Hospital of Sichuan University. Informed consents from
the patients were obtained for study of the resection spec-
imens.
Histology
Fresh CRC samples were received after resection, fixed in
10% pH-neutral formalin, embedded in paraffin. All the
patients had the diagnosis of adenocarcinomas and were
staged according to the American Joint Commission for
Cancer staging (AJCC/TNM, the sixth version) system.
Clinicopathological characteristics in our study included
age, gender, tumor size, degree of histological differentia-
tion (well/moderate/poor, WHO), depth of infiltration,
staging, and status of lymph nodes and liver metastases.
All histological slides were reviewed by two senior pathol-
ogists from our institution to confirm the diagnoses, and
to evaluate the patterns and intensity of HIF-1α and VEGF
reactivity.
Immunohistochemistry
Immunohistochemistry was performed using the un-avi-
din-biotin complex technique named EnVision following
the manufacturer's instructions with the reagents supplied
together with the kit. Briefly, 4 μm-thick sections were cut
consecutively from formalin-fixed, paraffin-embedded
tissue. Sections were mounted on silanized slides and
allowed to dry overnight at 37°C. After deparaffinization
and rehydratation, slides were incubated with 3% hydro-
gen peroxide solution for 5 min. After a washing proce-
dure with the supplied buffer, tissue sections were
repaired for 40 min with ethylenediamine tetraacetic acid.
The slides were again incubated with the primary anti-
body for 60 min at 37°C and then overnight at 4°C. TheBMC Cancer 2009, 9:432 http://www.biomedcentral.com/1471-2407/9/432
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primary polyclonal rabbit antibody (HIF-1α, Zymed) and
monoclonal mouse antibody (VEGF, DakoCytomation)
were both diluted at 1:50. After three rinses in buffer, the
slides were incubated with the secondary antibodies
(unbiotinylated antibody, EnVisionTM System, HRP,
anti-mouse/rabbit, DakoCytomation). Tissue staining
was visualized with a DAB substrate chromogen solution
(DakoCytomation). Slides were counterstained with
hematoxylin, dehydrated, and mounted. Each run
included, for each patient, phosphate buffered solution
(PBS) used as the primary antibody for the negative con-
trols, while samples known to express HIF-1α and VEGF
strongly served as the positive controls (Figure 1,2).
Scoring criteria
Five fields of vision by high power lens (×400) were
selected randomly and 200 cells were counted per field.
Then the percentage of positive cells was calculated. As
reported by others, HIF-1α cores were scored according to
the presence of nuclear and cytoplasmic staining [14].
Because the level of HIF-1α that is required to initiate
transcription is currently unknown, and the range of
staining intensity was narrow, the HIF-1α cores were
scored only according to the presence (1+) or absence (0)
of nuclear and cytoplasmic expression. Positive expres-
sion was defined by staining of more than 1% of the
tumor area. Cytoplasmic immunoreactivity for VEGF was
evaluated according to the extent of staining, with staining
intensities scored as: 0, no cells stained; 1, less than 10%
of cells stained; 2, 11% to 50% of cells stained; 3, more
than 50% of cells stained. For statistical analysis, we
divided the patients into two groups, positive expression
being defined by observation of staining of more than
10% of the tumor area (scores 2-3) [15].
Statistical analyses
Statistical analyses were all performed using SPSS-11.5
software. To test for difference between positive and neg-
ative of HIF-1α and VEGF expression scores, the chi-
square analysis was performed for categorical variables.
Various typical factors were considered for univariate
analysis. The impact of HIF-1α and VEGF expression on
survival was assessed with the Kaplan-Meier method and
compared by the log-rank test. Multivariate analysis, con-
ducted with a backward stepwise application of Cox
regression was used to evaluate the influence of HIF-1α
and VEGF expression on survival. Spearman correlation
from ranks was used to analyze the interaction between




Of the 71 tumor tissues obtained, 31 cases (43%) located
in the sigmoid colon. The majority (84%) was well and
moderately differentiated adenocarcinoma. Of the all
patients at the time of diagnosis, 27 had lymph nodes
metastases and 11 had liver metastases. During the
referred range of years, 2001-2006, after resection, 42
patients received chemotherapy according to their stage III
or IV. The adjuvant chemotherapy for patients with stage
III CRC in our institution was a 5-fluorouracil (5 FU)/leu-
covorin-based regimen or with oxaliplatin. In metastatic
CRC, patients received either 5 FU with leucovorin in
combination with oxaliplatin or irinotecan. However, no
patients received such new therapeutic strategy as HIF-1α
Positive control of the patterns of HIF-1α expression Figure 1
Positive control of the patterns of HIF-1α expression. 
Samples known to express HIF-1α intensely served as the 
positive control repoted by Zhong.
Positive control of VEGF expression Figure 2
Positive control of VEGF expression. Samples used as 
the positive control of VEGF expression reported by Shibusa.BMC Cancer 2009, 9:432 http://www.biomedcentral.com/1471-2407/9/432
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and VEGF targeted therapy because targeting drugs of this
kind had not been prescribed.
HIF-1alpha and VEGF patterns of expression
The patterns of HIF-1α expression in tumor tissues, when
present, were mixed nuclear/cytoplasmic (Figure 3) and
HIF-1α was positive in 54.93%(39/71) of the patients
(Figure 4). HIF-1α protein was expressed strongly in the
epithelium around the tumor, especially in the necrosis
region, but not in normal mucosa. VEGF was positive in
56.34% of the tumors (Figure 5, 6) and 17.39% of normal
mucosa.
Relationship with clinical outcomes
In univariate analysis, neither the patterns of HIF-1α
expression nor VEGF expression was associated with fol-
lowing clinical parameters: age, sex, tumor size, degree of
histological differentiation, and depth of infiltration (P >
0.05). The difference of HIF-1α expression in different
stage, lymph nodes and liver metastases had statistical sig-
nificance (P < 0.001) (Table 1). Overexpression of HIF-1α
was found in tissue of stage III and stage IV, lymph nodes
and liver metastases. The difference of VEGF expression in
different stage, lymph nodes and liver metastases had sta-
tistical significance (P < 0.001) (Table 2).
In multivariate analysis, logistic regression retained a sig-
nificant association between HIF-1α expression and
tumor stage (P = 0.001), with the percentage of patients
whose tumors expressed HIF-1α being 8.640-fold higher
in TNM stage III + IV than TNM stage I + II (regression
coefficient = 2.156, relative risk = 8.640). There was no
significant association between VEGF expression and the
clinicopathological factors.
Impact of HIF-1  and VEGF expression on prognosis
Univariate prognostic analyses
With a total follow-up of 60 months, 42 of the 71 assess-
able patients were still alive and 29 patients were known
to have died. The 5-years overall survival (OS) for all
Immunohistochemical staining of HIF-1α in moderately dif- ferentiated colon adenocarcinomas (EnVision, ×200) Figure 3
Immunohistochemical staining of HIF-1α in moder-
ately differentiated colon adenocarcinomas (EnVi-
sion, ×200). Typical mixed nuclear/cytoplasmic 
immunostaining of HIF-1α.
Staining of immunohistochemistry of HIF-1α (EnVision,  ×400) Figure 4
Staining of immunohistochemistry of HIF-1α (EnVi-
sion, ×400). HIF-1α expression showing mixed nuclear and 
cytoplasmic staining.
Immunohistochemical staining of VEGF in colorectal cancer  (EnVision, ×200) Figure 5
Immunohistochemical staining of VEGF in colorectal 
cancer (EnVision, ×200). VEGF expression showing a 
strong cytoplasmic immunostaining.BMC Cancer 2009, 9:432 http://www.biomedcentral.com/1471-2407/9/432
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patients was 59.15%. Analysis of the impact of negative or
positive HIF-1α expression composite score on OS is
shown in Figure 7. The 5-years OS for patients with nega-
tive and positive HIF-1α expression was 75% and 46%
respectively. Patients with HIF-1α positive tumors tended
to have poorer prognosis than did patients with negative
tumors. The expression of HIF-1α was negatively associ-
ated with the survival time of patients (P < 0.01) (log-rank
test). The 5-years OS of patients with negative and positive
VEGF expression was 83.87%(26/31) and 40% (16/40).
The survival time of patients with VEGF positive expres-
sion was significantly shorter than that of patients with
VEGF negative expression (P < 0.01) (Figure 8).
Multivariate analysis and Cox's proportional hazard model
According to our multivariate analysis (Cox model), using
all the influential factor variables HIF-1α and VEGF, HIF-
1α expression (P = 0.02) remained significantly associated
with OS (RR = 2.69, 95% confidence interval, 1.15-6.30)
and VEGF expression (P = 0.81) had no significant associ-
ation with prognosis (RR = 1.13, 95%CI, 0.41-3.09).
There was a trend toward poorer survival among the
patients of VEGF positive expression. Multivariate analysis
Staining of VEGF in colorectal cancer cells (EnVision, ×400) Figure 6
Staining of VEGF in colorectal cancer cells (EnVision, 
×400). Typical cytoplasmic immunoreactivity of VEGF.
Table 1: Association between HIF-1α and clinicopathological factors
Factors No. of patients HIF-1α
Positive expression χ2 P
Age
<60 24 15(62.5%) 0.839 0.363
≥ 60 47 24(51.1%)
Sex
Male 43 24(55.8%) 0.034 0.853
Female 28 15(53.6%)
Tumor size
<5 cm 31 17(54.8%) 0.000 0.989
≥ 5 cm 40 22(55%)
Differentiation
grade




T1 + T2 10 6(60%) 0.121 0.728
T3 + T4 61 33(54.1%)
Tumor stage
I+II 42 15(35.7%) 15.336 <0.001
III+IV 29 24(82.8%)
lymphnode matastasis,
No 44 17(38.6%) 12.007 <0.001
Yes 27 22(81.5%)
liver matastasis
NO 60 29(48.3%) 6.806 0.009
Yes 11 10(90.1%)BMC Cancer 2009, 9:432 http://www.biomedcentral.com/1471-2407/9/432
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Table 2: Relationship between VEGF and clinicohistological features
Factors No. of patients VEGF
Positive expression χ2 P
Age
<60 24 14(58.3%) 0.059 0.809
≥ 60 47 26(55.3%)
Sex
Male 43 25(58.1%) 0.144 0.704
Female 28 15(53.6%)
Tumor size
<5 cm 31 19(61.3%) 0.549 0.459
≥ 5 cm 40 21(52.5%)
Differentiation
grade




T1 + T2 10 5(50%) 0.190 0.663
T3 + T4 61 35(57.4%)
Tumor stage
I+II 42 12(28.6%) 32.229 <0.001
III+IV 29 28(96.6%)
lymphnode matastasis,
No 44 14(31.8%) 28.280 <0.001
Yes 27 26(96.3%)
Liver matastasis
NO 60 30(50%) 6.324 0.012
Yes 11 10(90.9%)
Kaplan--Meier overall survival (OS) curves for 71 patients  with colorectal cancer Figure 7
Kaplan--Meier overall survival (OS) curves for 71 
patients with colorectal cancer. Patients with HIF-1α 
positive expression had a significantly worse OS compared 
with those with HIF-1α negative expression.
Impact of VEGF expression on the patients' overall survival  (log-rank test) Figure 8
Impact of VEGF expression on the patients' overall 
survival (log-rank test). The survival time of patients with 
VEGF positive expression was significantly shorter than that 
of patients with negative expression.BMC Cancer 2009, 9:432 http://www.biomedcentral.com/1471-2407/9/432
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identified that HIF-1α was statistically significant as an
independent prognostic factor for OS.
Correlation of HIF-1alpha and VEGF expression in 
colorectal cancer
Of the 39 patients with positive HIF-1α expression, 34
patients were investigated with positive VEGF expression.
Positive expression of VEGF was detected in 34 patients.
While of the 32 patients with negative HIF-1α expression,
27 patients were evaluated with negative VEGF expres-
sion. Negative expression of VEGF was evaluated in 27
patients. Spearman analysis showed the expression of
HIF-1α was positively correlative to VEGF (r = 0.716, P <
0.001) in CRC (Table 3).
Discussion
The main findings of the present study are that HIF-1α
and VEGF expression were significantly associated with
advanced stage and implied poor prognosis in patients
with CRC. Moreover, in multivariate analysis overexpres-
sion of HIF-1α was an independent prognostic factor for
OS.
As we know, HIF-1 and VEGF are important regulators of
angiogenesis [16]. HIF-1 is a heterodimer composed of
HIF-1α and HIF-1β subunits. HIF-1β also known as aryl
hydrocarbon receptor nuclear translocator, is constitu-
tively expressed, whereas HIF-1α is protected from ubiq-
uitination and proteasomal degradation under hypoxic
conditions [17]. HIF-1α activates transcription of genes
encoding glucose transporters, glycolytic enzymes, and
VEGF. HIF-1α activates the expression of VEGF gene by
binding to the HRE in the VEGF promoter region [18].
Tumor angiogenesis is stimulated by angiogenic inducers
involving VEGF, basic fibroblast growth factor (bFGF),
transforming growth factor (TGF) and interleukin 8 (IL-8)
[19]. HIF-1α and VEGF are major regulators of angiogen-
esis [20] and are important in tumor progression [21].
This study was performed to evaluate retrospectively HIF-
1α and VEGF immunohistochemical reactivity in CRC
patients and to explore the association of the expression
with clinicopathological characteristics and prognosis.
HIF-1α was found to be overexpressed in 13 of 19 tumor
types compared with the respective normal tissues,
including colon, breast, gastric, lung, skin, ovarian, pan-
creatic, prostate, and renal carcinomas [22-25]. HIF-1α
was overexpressed in primary and metastatic human
tumors [26-30]. Our study shows that HIF-1α expression
was positive in 54.93%(39/71) of CRC but negative in
normal mucosa. The tumor cells surrounding necrotic
regions expressed high levels of HIF-1αprotein. VEGF was
positive in 56.34% of tumors and 17.39% of normal
mucosa. The levels of expression of HIF-1α and VEGF in
tumor cells were both higher than those in normal cells.
Through the research, we have found that the expression
of HIF-1α in different age, sex, tumor size, degree of histo-
logical differentiation, and depth of infiltration had no
difference(P > 0.05). Consistent with the results of the
major studies published to date [31,32], the difference of
HIF-1α expression in different stage, lymph nodes and
liver metastases had statistical significance(P  < 0.001).
Overexpression of HIF-1α was found in tissue of stage III
+ IV, lymph nodes and liver metastases. In multivariate
analysis, logistic regression confirmed a significant associ-
ation between HIF-1α expression and tumor stage. In uni-
variate analyses, VEGF expression was significantly
associated with different stage, lymph nodes and liver
metastases(P < 0.001). Initially concluded, the positive
expression of HIF-1α and VEGF was significantly associ-
ated with advanced stage and seemed to reflect more
aggressive histological and clinicalbehaviors. HIF-1α and
VEGF could be biomarkers indicating tumor infiltration
and metastasis evaluation in CRC.
Previous studies suggest that HIF-1α positivity was associ-
ated with both TNM stage and vascular invasion in rectal
cancer [33]. In the present study we focused on the clinical
and prognostic implications of the expression of HIF-1α
and VEGF in patients with CRC, not only rectal cancer.
Our results shows that the 5-years OS of patients with neg-
ative and positive HIF-1α expression was 75% and 46%,
respectively. Patients with positive HIF-1α tumors had a
statistically significant poorer prognosis in comparison
with patients with negative HIF-1α tumors (P < 0.01).
VEGF is a survival factor for tumor endothelium in a
marine model of colorectal carcinoma with liver metas-
tases [34]. In our study, the 5-years OS of patients with
negative and positive expression of VEGF was 83.87%(26/
31) and 40% (16/40). The survival time of patients with
VEGF positive expression was significantly shorter than
that of patients with negative expression (P < 0.01). As a
result, the positive expression of HIF-1α and VEGF both
implied poor prognosis.
In multivariate analysis of Cox model, HIF-1α was an
independent prognostic variable for OS (RR = 2.69).
VEGF had a trend to be a risk factor of mortality (RR =
1.129) but no statistically significant association with-
prognosis. This different finding about VEGF in univariate
and multivariate analysis should logically encourage us to
continue our investigations and enlarge sample size. The
Table 3: Correlation between HIF-1α and VEGF in CRC
VEGF
HIF-1α r 0.716
P <0.001BMC Cancer 2009, 9:432 http://www.biomedcentral.com/1471-2407/9/432
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present study reinforces the evidence which implies that
positive expression of HIF-1α has poor prognosis, maybe
the same with VEGF. This study shows that HIF-1α expres-
sion is significantly associated with prognosis of patients
in CRC.
HIF-1α expression is evaluated in many human cancers
and HIF-1α levels of expression in cells correlate with
tumorigenicity and angiogenesis [32]. Spearman analysis
shows the expression of HIF-1α was positively correlative
to VEGF(r = 0.72, P < 0.001) in CRC. However, efforts of
further research are required to determine the precise cor-
relation between HIF-1α and VEGF.
Conclusion
Angiogenesis is an early event in carcinogenesis and plays
an important role in tumor growth. In line with the
expression of VEGF, one of the key angiogenic factors reg-
ulating VEGF is HIF-1α. HIF-1α and VEGF might be used
as biomarkers indicating tumor infiltration and poor
prognosis in human CRC. Inhibition of HIF-1α might be
a promising targeted antiangiogenic therapy in CRC to
exhibit its potential to improve outcomes in future per-
spective, just as VEGF targeting has proved to be.
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